|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Walter Reed Army Medical Center |
| Information provided by: | Walter Reed Army Medical Center |
| ClinicalTrials.gov Identifier: | NCT00413751 |
Purpose
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
| Condition | Intervention |
|
Healthy |
Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) |
| ChemIDplus related topics: | Brimonidine Brimonidine Tartrate |
| Study Type: | Observational |
| Study Design: | Longitudinal, Convenience Sample, Prospective Study |
Eligibility
| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, District of Columbia | |||||
| Walter Reed Army Medical Center | |||||
| Washington, District of Columbia, United States, 20307 | |||||
| Walter Reed Army Medical Center |
| Principal Investigator: | KRAIG S. BOWER, MD | Walter Reed Army Medical Center |
More Information
| Study ID Numbers: | WRAMC WU #03-23004 |
| First Received: | December 19, 2006 |
| Last Updated: | December 19, 2006 |
| ClinicalTrials.gov Identifier: | NCT00413751 |
| Health Authority: | United States: Federal Government |
|
|
|
|